A Trial of Baricitinib in Patients With Cardiac Sarcoidosis (NCT06868381)
A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT? Participants will: * Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib
Who can join: Review the eligibility criteria below.
Location: Stanford University — Palo Alto, California
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Stanford University — Palo Alto, California
📞 Contact the Study Coordinator
Phone: (650) 723-8516
Email: aberia@stanford.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiac Sarcoidosis
- Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression — Philadelphia, Pennsylvania
- Cardiac Sarcoidosis Multi-Center Prospective Cohort — Calgary, Alberta
- Repurposing Tilmanocept for Cardiac Sarcoidosis — Durham, North Carolina
- Cardiac Sarcoidosis Randomized Trial — New Haven, Connecticut
- Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS) — Rochester, Minnesota
Explore by condition: All Cardiac Sarcoidosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.